The use of pramipexole in Parkinson's disease:: are its actions D3 mediated?

被引：27

作者：

Guttman, M ^{[1
]}

Jaskolka, J

机构：

[1] Univ Toronto, Natl Parkinson Fdn Ctr Excellence, Div Neurol, Dept Med, Toronto, ON, Canada

[2] Univ Toronto, Natl Parkinson Fdn Ctr Excellence, Dept Psychiat, Toronto, ON, Canada

[3] Ctr Addict & Mental Hlth, Toronto, ON, Canada

来源：

PARKINSONISM & RELATED DISORDERS | 2001年 / 7卷 / 03期

关键词：

pramipexole; Parkinson's disease; D-3 dopamine receptor;

D O I：

10.1016/S1353-8020(00)00062-6

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Pramipexole is a non-ergot dopamine agonist recently approved for the treatment of early and advanced Parkinson's disease (PD). It has preferential affinity for the D-3 dopamine receptor, compared to previous dopamine agonists that have higher affinity for D-2 dopamine receptors. The ultimate question is whether its efficacy is linked to its action at the D-3 dopamine site or due to its binding to D-2 dopamine receptors. There is no direct experimental evidence available to answer this question. Based on a review of the pharmacological literature, it is likely that the motor benefits of pramipexole in PD patients are due to D-2 stimulation, whereas its putative effects on mood and apathy may be related to its D3 agonist properties. (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：231 / 234

页数：4

共 26 条

[1] Induction of dopamine D-3 receptor expression as a mechanism of behavioral sensitization to levodopa [J].

Bordet, R ;

Ridray, S ;

Carbon, S ;

Diaz, J ;

Sokoloff, P ;

Schwartz, JC .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (07) :3363-3367

[2] BROMOCRIPTINE IN PARKINSONISM [J].

CALNE, DB ;

TEYCHENNE, PF ;

CLAVERIA, LE ;

EASTMAN, R ;

GREENACRE, JK ;

PETRIE, A .

BMJ-BRITISH MEDICAL JOURNAL, 1974, 4 (5942) :442-444

[3]

CALNE DB, 1993, NEW ENGL J MED, V329, P1021

[4]

Cummings JL, 1999, J NEUROL SCI, V163, P2

[5]

GOPINATHAN G, 1989, DRUGS TREATMENT PARK, P471

[6]

GRIFFON N, 1995, CLIN NEUROPHARMACOL, V18, pS130

[7] L-DOPA REVERSES THE ELEVATED DENSITY OF D-2 DOPAMINE-RECEPTORS IN PARKINSONS DISEASED STRIATUM [J].

GUTTMAN, M ;

SEEMAN, P .

JOURNAL OF NEURAL TRANSMISSION, 1985, 64 (02) :93-103

[8] DOPAMINE-D2 RECEPTOR DENSITY REMAINS CONSTANT IN TREATED PARKINSONS-DISEASE [J].

GUTTMAN, M ;

SEEMAN, P ;

REYNOLDS, GP ;

RIEDERER, P ;

JELLINGER, K ;

TOURTELLOTTE, WW .

ANNALS OF NEUROLOGY, 1986, 19 (05) :487-492

[9] Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease [J].

Guttman, M ;

Ott, E ;

Tragner, H ;

Bedard, PJ ;

Pourcher, E ;

Curran, T ;

Goodridge, A ;

Guttman, M ;

Hobson, D ;

King, D ;

Martin, WRW ;

Mendis, T ;

Rajput, A ;

Rivest, J ;

Stoessl, J ;

Suchowersky, O ;

Moran, J ;

Murphy, R ;

Walsh, B ;

ONeill, DO ;

Klemperer, B ;

Martin, M ;

Oehlwein, C ;

Polzer, U ;

Reichmann, H ;

Schimek, J ;

Schlenker, M ;

Schwartz, A ;

Meier, D ;

Traubner, P ;

Benetin, J ;

Bomhof, MAM ;

Hovestadt, A ;

Vreeling, FW ;

Wolters, ECMJ ;

Broddie, HG ;

Clarke, C ;

Clough, CJ ;

Loizou, L ;

Newman, PK ;

Pye, IF .

NEUROLOGY, 1997, 49 (04) :1060-1065

[10] Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease [J].

Hutton, JT ;

Koller, WC ;

Ahlskog, JE ;

Pahwa, R ;

Hurtig, HI ;

Stern, MB ;

Hiner, BC ;

Lieberman, A ;

Pfeiffer, RF ;

Rodnitzky, RL ;

Waters, CH ;

Muenter, MD ;

Adler, CH ;

Morris, JL .

NEUROLOGY, 1996, 46 (04) :1062-1065

← 1 2 3 →